COS.L

Collagen Solutions Plc
Collagen Sol PLC - Collagen Solutions Acquired by Rosen’s Diversified
20th October 2020, 06:03
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5425C
Collagen Solutions PLC
20 October 2020
 

 

 

20 October 2020

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Collagen Solutions Plc Acquired by Rosen's Diversified, Inc.

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that today Rosen's Diversified, Inc. ("RDI") declared that its offer to acquire Collagen Solutions plc (the "Offer") had become wholly unconditional and as a result, Collagen Solutions will become part of the RDI Group.

 

RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Minnesota near the Company's U.S. offices. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.

 

Jamal Rushdy, CEO of Collagen Solutions said: "We have made tremendous progress in our vision to be the industry's first choice for regenerative biomaterials. We believe that being part of RDI will generate significant growth opportunities and create enhanced value for the benefit of all stakeholders and in particular our employees, customers and suppliers. I am optimistic and excited for the potential for continued momentum and greater opportunity for Collagen Solutions." 

 

Wade Rosen, Director of RDI and Executive Vice President of Corporate Development of SLS said: "Collagen Solutions represents an attractive strategic and cultural fit with SLS and we have been highly impressed by the long-term vision and ethos of the Company. The successful completion of the Offer will now provide a foundation for SLS to become a major tissue provider in North America, leveraging the RDI Group's local porcine and bovine harvest, logistics and distribution capabilities in the United States. Collagen's international presence will also provide a platform for SLS to extend its supply of porcine and bovine tissue into the EMEA and APAC regions."

 

England & Company, LLC and Goodbody Stockbrokers UC acted, in relation to the Offer, as joint financial advisers to Collagen Solutions.  Shepherd and Wedderburn LLP acted as legal adviser to Collagen Solutions.

 

Strand Hanson and Faegre Drinker acted, in relation to the Offer, as sole financial adviser and legal adviser to RDI, respectively.

 

Enquiries:

Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO

via Walbrook

England & Company LLC
(Joint Financial Adviser to Collagen Solutions Plc)
Craig England
Paul Teitelbaum

Tel: +1 (212) 235-0850

Goodbody Stockbrokers UC
(Rule 3 Adviser and Joint Financial Adviser to Collagen Solutions Plc)
Stephen Kane
Christopher McAuliffe

Tel: +353 (0) 1 667 0400

Cenkos Securities plc
(Nominated Adviser and Broker to Collagen Solutions Plc)
Giles Balleny
Max Gould

Tel: +44 (0) 207 397 8900

Walbrook PR Ltd
(Financial PR adviser to Collagen Solutions Plc)
Anna Dunphy

Tel: +44 (0) 207 933 8780
or collagen@walbrookpr.com

Mob: +44 (0) 7876 741 001

Rosen's Diversified, Inc.
David Krawitz, Director of Strategy, Operations and Sales

Tel: +1 (612) 406-5181

Strand Hanson Limited
(Financial Adviser to Rosen's Diversified, Inc.)
Stuart Faulkner
Matthew Chandler
James Dance
Jack Botros

Tel: +44 (0) 207 409 3494

Important Notice

England & Company LLC, through its wholly owned subsidiary, England Securities, LLC, is acting as joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of England & Company LLC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither England & Company LLC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of England & Company LLC in connection with this announcement, any statement contained herein or otherwise.

Goodbody Stockbrokers UC, trading as Goodbody, which is regulated in Ireland by the Central Bank of Ireland and in the UK by the Financial Conduct Authority, is acting as sole Rule 3 adviser and joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Goodbody Stockbrokers UC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Goodbody Stockbrokers UC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goodbody Stockbrokers UC in connection with this announcement, any statement contained herein or otherwise.

Cenkos Securities plc, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Cenkos Securities plc nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein.  Neither Cenkos Securities plc nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cenkos Securities plc in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQDGBDGLXBDGGC ]]>
TwitterFacebookLinkedIn